Aortic & peripheral vascular diseaseCohort study
Device Effectiveness for Femoropopliteal Artery Disease Treatment
- Registry cohort study
- multicentre
- inverse probability of treatment weighting
Authors' conclusion
In real-world practice, DCBs and DES demonstrated comparably superior midterm outcomes over POBA or BMS in the treatment of FPA lesions.
Study context
- Population
- Limbs undergoing percutaneous transluminal angioplasty for femoropopliteal artery lesions, K-VIS ELLA registry, 2012–2020limbs
- Participants
- 826 / 943 / 778 / 227
- Exposure
- Drug-coated balloons (DCBs) or drug-eluting stents (DES) vs bare-metal stents (BMS) for femoropopliteal artery (FPA) disease
- Plain old balloon angioplasty (POBA)n = 826
- BMSn = 943reference
- DCBsn = 778
- DESn = 227
- Outcome
- Target lesion revascularization (TLR)
- Follow-up
- 2 years
Main finding
As reported in the abstract
TLR
Hazard ratio (95% CI)P value
DCBs vs BMS
0.44(0.30–0.64)
P < 0.001DES vs BMS
0.51(0.29–0.87)
P = 0.014DCBs vs DES
0.87(0.51–1.49)
P = 0.613POBA vs BMS
0.94(0.73–1.21)
P = 0.626Observational data: associations, not effects.
Further findings
All-cause mortality
- Comparable in the 4 groups
Target lesion revascularization (TLR) in TASC II type C/D or long lesions (≥150 mm) (subgroup)
- More pronounced favourable outcome with DCBs vs POBA, BMS or DES
- P for interaction < 0.05
- interaction P< 0.05
Original publication
Device Effectiveness for Femoropopliteal Artery Disease Treatment. JACC Cardiovasc Interv. Published 10 July 2023. doi:10.1016/j.jcin.2023.05.002
Summarised from the published abstract; every number is checked against it